Inquiry Basket
Loading ......
Filter By Product Search for
C. pneumoniae LPS
C. pneumoniae LPS Full Name
Chlamydia Pneumoniae lipopolysaccharide
C. pneumoniae LPS Introduction
The lipopolysaccharide (LPS) of Chlamydophila pneumoniae represents a key surface component that contributes to bacterial structure, pathogenesis, and host immune responses, although it differs significantly from the LPS of enteric Gram-negative bacteria in both structure and biological activity, which serves as the immunodominant epitope recognized by genus-specific antibodies. Unlike the highly variable O-antigen polysaccharides of enteric bacteria, chlamydial LPS lacks extended O-antigen chains and is more accurately termed lipooligosaccharide (LOS). This genus-specific antigen is shared among all Chlamydiaceae species and has been utilized in serological assays for detecting chlamydial infections, although the cross-reactivity between species limits its utility for species-specific diagnosis. The biosynthesis of chlamydial LOS involves the enzyme LpxC (UDP-3-O-(R-3-hydroxymyristoyl)-GlcNAc deacetylase), which catalyzes the first committed step in lipid A synthesis, and inhibitors of this enzyme have been shown to block LOS synthesis in Chlamydia trachomatis.
The role of C. pneumoniae LPS in pathogenesis extends beyond structural functions to include activation of innate immune responses through pattern recognition receptors, particularly. LPS-mediated inflammation may contribute to the chronic inflammatory processes implicated in atherosclerosis and other diseases associated with C. pneumoniae infection. Studies have demonstrated that chlamydial LPS can induce proinflammatory cytokine production (IL-1β, IL-6, IL-8, TNF-α), endothelial cell activation, upregulation of adhesion molecules, and foam cell formation in macrophages, all of which are relevant to atherogenesis. The relatively low endotoxic activity of chlamydial LPS compared to enterobacterial LPS may reflect structural differences in the lipid A moiety, but the chronic, persistent nature of chlamydial infection may result in sustained low-level inflammation that contributes to tissue damage over time. Recent studies using LpxC inhibitors have revealed that LOS is required for the developmental transition from reticulate bodies to infectious elementary bodies in Chlamydia trachomatis, suggesting that LOS plays essential roles in the chlamydial developmental cycle beyond immune activation.
The immunological properties of C. pneumoniae LPS have implications for both diagnostic applications and vaccine development. Serological assays based on chlamydial LPS, including complement fixation tests and some ELISA formats, detect genus-specific antibodies but cannot differentiate between infections caused by different Chlamydiaceae species, limiting their clinical utility in settings where multiple chlamydial species may be encountered. Species-specific diagnosis requires assays based on antigens with greater specificity, such as MOMP or species-specific proteins. For vaccine development, the conserved nature of chlamydial LPS across species could theoretically provide a basis for broadly protective vaccines, although the relatively weak immunogenicity of LPS compared to protein antigens and concerns about endotoxic activity have limited its development as a vaccine component. Understanding the structure-function relationships of chlamydial LPS and its interactions with host immune receptors continues to inform research into chlamydial pathogenesis and may reveal novel therapeutic targets for preventing or treating the chronic inflammatory complications associated with C. pneumoniae infection.
Alternate Names for C. pneumoniae LPS
C. Pneumoniae; Chlamydia Pneumoniae; Chlamydiaceae; Chlamydia; Taiwan acute respiratory agent; TWAR; LPS; lipopolysaccharide; C. Pneumoniae lipopolysaccharide; Chlamydia Pneumoniae lipopolysaccharide; C. Pneumoniae LPS; Chlamydia Pneumoniae LPS
Loading ......
